GlassScriptPhysician profile
Elise Johnston
NPI 1639896061
$4,960.55
in general payments reported to CMS, 2019-2025
27 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $421 · 2024: $4,279 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Travel and Lodging: $1,684 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.88 |
| Travel and Lodging | $1,683.77 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,917.22 | 2024 | Axonics |
| Teleflex LLC | $1,083.13 | 2023-2024 | Urolift |
| Dendreon Pharmaceuticals LLC | $209.00 | 2023-2024 | Provenge |
| Astrazeneca Pharmaceuticals LP | $179.94 | 2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $165.07 | 2024 | |
| Procept Biorobotics Corporation | $160.37 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $159.47 | 2023-2024 | Erleada, Akeega |
| Viewray Technologies INC | $133.72 | 2022 | |
| Astellas Pharma US INC | $129.82 | 2024 | Xtandi |
| Sumitomo Pharma America, INC. | $117.80 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $90.41 | 2023-2024 | Pylarify |
| Valencia Technologies Corporation | $87.78 | 2023 | Ecoin Device Kit |
| Endo USA, INC. | $71.40 | 2024-2025 | Aveed, Xiaflex, Edex |
| Abbvie INC. | $59.73 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.88 | 2023 | Keytruda, Lynparza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $56.96 | 2024-2025 | |
| Bluewind Medical | $42.77 | 2024 | Revi |
| Endo Pharmaceuticals INC. | $41.16 | 2023 | Aveed, Xiaflex, Edex |
| Antares Pharma, INC. | $30.28 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Blue Earth Diagnostics | $25.94 | 2024 | |
| Olympus America INC. | $22.19 | 2023 | Itind System |
| Coloplast Corp | $21.41 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.81 | 2023 | |
| Boston Scientific Corporation | $19.90 | 2023 | Spaceoar System |
| Tolmar, INC. | $18.53 | 2024 | |
| Telix Pharmaceuticals | $18.49 | 2024 | Illuccix |
| Galderma Laboratories, L.P. | $18.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.